Seguir
Manuel Hidalgo
Manuel Hidalgo
Weill Cornell Medicine
Dirección de correo verificada de med.cornell.edu
Título
Citado por
Citado por
Año
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
DD Von Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore, T Seay, ...
New England journal of medicine 369 (18), 1691-1703, 2013
70302013
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
S Jones, X Zhang, DW Parsons, JCH Lin, RJ Leary, P Angenendt, ...
science 321 (5897), 1801-1806, 2008
47422008
Pancreatic cancer
M Hidalgo
New England journal of medicine 362 (17), 1605-1617, 2010
35762010
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ...
New England Journal of Medicine 373 (8), 726-736, 2015
19492015
Patient-derived xenograft models: an emerging platform for translational cancer research
M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ...
Cancer discovery 4 (9), 998-1013, 2014
17362014
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
A Jimeno, G Feldmann, A Suárez-Gauthier, Z Rasheed, A Solomon, ...
Molecular cancer therapeutics 8 (2), 310-314, 2009
1575*2009
Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab
S Khambata-Ford, CR Garrett, NJ Meropol, M Basik, CT Harbison, S Wu, ...
Journal of clinical oncology 25 (22), 3230-3237, 2007
14132007
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo, LL Siu, J Nemunaitis, J Rizzo, LA Hammond, C Takimoto, ...
Journal of clinical oncology 19 (13), 3267-3279, 2001
12692001
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
DD Von Hoff, RK Ramanathan, MJ Borad, DA Laheru, LS Smith, TE Wood, ...
Journal of Clinical Oncology 29 (34), 4548-4554, 2011
12552011
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
CA Iacobuzio-Donahue, B Fu, S Yachida, M Luo, H Abe, CM Henderson, ...
Journal of clinical oncology 27 (11), 1806-1813, 2009
11982009
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins, M Hidalgo, WM Stadler, TF Logan, JP Dutcher, GR Hudes, ...
Journal of clinical oncology 22 (5), 909-918, 2004
11912004
Development of matrix metalloproteinase inhibitors in cancer therapy
M Hidalgo, SG Eckhardt
Journal of the National Cancer Institute 93 (3), 178-193, 2001
11122001
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of …
D Soulieres, NN Senzer, EE Vokes, M Hidalgo, SS Agarwala, LL Siu
Journal of clinical oncology 22 (1), 77-85, 2004
10072004
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
E Galanis, JC Buckner, MJ Maurer, JI Kreisberg, K Ballman, J Boni, ...
Journal of Clinical Oncology 23 (23), 5294-5304, 2005
8462005
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
M Hidalgo, EK Rowinsky
Oncogene 19 (56), 6680-6686, 2000
7842000
Interrogating open issues in cancer precision medicine with patient-derived xenografts
AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ...
Nature Reviews Cancer 17 (4), 254-268, 2017
6942017
Developing inhibitors of the epidermal growth factor receptor for cancer treatment
V Grunwald, M Hidalgo
Journal of the National Cancer Institute 95 (12), 851-867, 2003
6672003
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
I Garrido-Laguna, M Hidalgo
Nature reviews Clinical oncology 12 (6), 319-334, 2015
6432015
Addressing the challenges of pancreatic cancer: future directions for improving outcomes
M Hidalgo, S Cascinu, J Kleeff, R Labianca, JM Löhr, J Neoptolemos, ...
Pancreatology 15 (1), 8-18, 2015
6202015
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma
ZA Rasheed, J Yang, Q Wang, J Kowalski, I Freed, C Murter, SM Hong, ...
Journal of the National Cancer Institute 102 (5), 340-351, 2010
5382010
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20